FOXO4-DRI and senolytic peptides: one mouse paper and a market

Senescent cells and the senolytic idea

As cells are damaged, some stop dividing for good but refuse to die. These senescent cells accumulate with age and release inflammatory signals that can harm the tissue around them. Removing them genetically in mice delays features of ageing, which raised a tantalising possibility: a drug that selectively killed senescent cells, a senolytic, might treat several age-related conditions at once ¹.

The challenge is selectivity. Senescent cells survive by switching on pathways that hold off programmed cell death, and a senolytic has to switch those off in senescent cells without harming healthy ones. Small-molecule senolytics such as dasatinib, quercetin and fisetin, and drugs that block survival proteins, came first. FOXO4-DRI took a different approach.

What FOXO4-DRI is

In senescent cells, the protein FOXO4 binds p53, the cell's main guardian against damage, and keeps it in the nucleus in a way that prevents it from triggering death. In 2017, Baar and colleagues designed a peptide that interferes with that interaction. In senescent cells it caused p53 to leave the nucleus and set off cell-intrinsic apoptosis, while sparing normal cells ¹.

The peptide is made from D-amino acids, the mirror images of the amino acids in natural proteins, assembled in reverse order, a 'D-retro-inverso' design that resists the enzymes that break down ordinary peptides, and it carries a cell-penetrating segment to get inside cells ². A 2025 study solved the structure of its interaction: the disordered FOXO4-DRI binds a disordered region of p53 and forms a transiently folded complex, with both the FOXO4-derived part and the cell-penetrating part contributing ³.

The 2017 mouse study

The results that made headlines came from mice. Under conditions where it was well tolerated, FOXO4-DRI neutralised the toxicity of the chemotherapy drug doxorubicin, and it restored fitness, fur density and kidney function both in mice engineered to age rapidly and in naturally aged mice ¹. For a field searching for a way to clear senescent cells selectively, it was a striking demonstration.

It was also one study, in mice, from the group that designed the peptide. Its doses, schedules and safety findings apply to mice; how a peptide behaves in a mouse says little about how it is absorbed, distributed or tolerated in a person, and the effects that looked like rejuvenation were measured over weeks in animals with short lifespans.

What has followed

Since 2017, FOXO4-DRI has been studied in cells and animals for a range of conditions ^{4 5 6 7 8 3}:

In aged mice, it improved testosterone secretion by targeting senescent Leydig cells in the testes ⁴ and improved sperm production ⁷. In human cartilage cells grown in the laboratory for transplantation, it removed senescent cells that impair cartilage quality ⁵. In mice with chemically induced lung scarring, it reduced fibrosis ^{6 9}, and in human keloid fibroblasts it induced apoptosis of senescent cells ⁸. Every one of these is a cell or animal study. As of October 3, 2026, no human trial of FOXO4-DRI has been published or is recruiting, and no application to FDA exists ².

Is clearing senescent cells always good?

Not necessarily. Senescence is also a defence: it stops damaged cells from dividing and becoming cancerous, and senescent cells play roles in wound healing. A 2023 study in Circulation found that in mice exposed to low oxygen, eliminating senescent cells, by a genetic 'suicide' switch or the senolytic drug ABT263, increased pressure in the right side of the heart, worsened vessel remodelling and markedly reduced the lung's endothelial cells, promoting pulmonary hypertension rather than preventing it ¹⁰. The finding did not test FOXO4-DRI, but it shows that removing senescent cells can harm some tissues. A drug that kills cells is not automatically rejuvenating.

How senolytic drugs have fared in people

The small-molecule senolytics have at least reached people, and their results are a useful reality check. In a phase 1 pilot in idiopathic pulmonary fibrosis, intermittent dasatinib plus quercetin was feasible and generally tolerated, with no serious adverse events attributed to it, but sleep disturbance and anxiety were more common, and frailty, lung and physical function did not appear to differ, in a trial too small to tell ¹¹. In a phase 2 randomised trial in 60 postmenopausal women, intermittent dasatinib plus quercetin did not change the primary bone-resorption marker at 20 weeks, though a bone-formation marker rose early ¹². A pilot in early Alzheimer's disease tested whether the combination reached the brain ¹³. A related senolytic that blocks the p53-MDM2 interaction, UBX0101, reduced oxidative damage in aged mouse knees, with weaker benefit in old animals than young ¹⁴. Trials of fisetin, a plant flavonoid with senolytic activity in the laboratory, are also under way, including a multicentre randomised trial in older patients with sepsis whose protocol was published in 2024 ¹⁵.

Those are modest, early results for drugs with decades of safety data in other uses. FOXO4-DRI has none of that history: no human pharmacology, no safety data and no manufacturing standard.

The measurement problem

Even for the senolytics in human trials, a basic question is hard: how many senescent cells does a person have, and did the drug remove them? In mice, researchers can count cells in tissue; in people, they need blood markers. Investigators from the postmenopausal bone trial reported that women whose T cells expressed the most of one form of the senescence marker p16 had the strongest bone responses to dasatinib plus quercetin, and that a panel of inflammatory proteins secreted by senescent cells in plasma performed as well at identifying them ¹⁶. That is progress towards selecting the right people for trials. It also shows how far the field is from the claim, common in peptide marketing, that a product 'clears zombie cells': nobody selling FOXO4-DRI can show that it has done so in a buyer.

Questions to ask about any anti-ageing peptide

• Has it been given to people in a published study, and what did that study measure: a disease outcome, a blood marker, or nothing beyond safety?
• Who did the research? A single group, or independent laboratories that reproduced it?
• Is the human claim backed by a human study, or only by mice and cells?
• For a product designed to kill cells or change cell survival, what is known about effects on tissues the marketing does not mention?
• Can the seller show, from an identified laboratory, that the vial contains the right molecule, including the correct mirror-image amino acids?

For FOXO4-DRI, the answers are no human study, one designing group for the key result with independent cell and mouse follow-ups, mouse evidence only, unknown off-target effects in people, and no standard against which to check a vial.

The market

FOXO4-DRI is sold online as a research peptide, sometimes as an anti-ageing injection, at prices that reflect its complex synthesis. Buyers cannot verify that a vial contains the correct D-amino acid peptide rather than an ordinary L-peptide, which would be broken down quickly, or something else entirely, without specialist testing. And because the peptide is designed to kill cells, a mistake in dose or selectivity is not a trivial risk. For athletes, it falls under WADA's S0 catch-all for non-approved substances ².

Other ageing-related peptides are sold the same way. Our entries on humanin and MOTS-c set out how far each has got, and our guide to reading a study explains why a single mouse paper is the start of a research programme, not evidence of a human benefit.

Why there is no human trial

Moving a compound like FOXO4-DRI into people would require manufacturing to pharmaceutical standards, toxicology studies in two species, and careful dose-finding, because a peptide that triggers cell death could cause harm if it is less selective in human tissue than in mouse cells. The 2017 authors described it as well tolerated under the conditions they used in mice ¹, which is a starting point for that work, not a substitute for it. Until such studies are done and published, nobody knows what FOXO4-DRI does in people.

The bottom line

As of October 3, 2026, FOXO4-DRI is a clever, well-characterised research peptide with an influential 2017 mouse study and a string of cell and animal follow-ups. It has never been given to a person in a published study, and it is not approved anywhere. Senolytic drugs that have reached people have produced mixed, early results, and clearing senescent cells is not always beneficial. A vial sold as FOXO4-DRI offers a peptide of unverified identity, designed to kill cells, with no human safety data.

Frequently asked questions

What is FOXO4-DRI?

A synthetic D-retro-inverso peptide designed to block FOXO4 from binding p53 in senescent cells, so that those cells undergo apoptosis. It was described in a 2017 mouse study.

Has FOXO4-DRI been tested in humans?

No. As of October 3, 2026, no human trial has been published or is recruiting, and it is not approved anywhere.

Do senolytics work in people?

Small trials of senolytic drugs such as dasatinib plus quercetin have shown feasibility but mixed results; a 60-woman bone trial missed its primary endpoint. No senolytic is approved for any ageing-related condition.

Is removing senescent cells safe?

Not always. In a mouse study, eliminating senescent cells worsened pulmonary hypertension, and senescence also protects against cancer and helps wound healing.

Related on Grey Peptides

• FOXO4-DRI
• Humanin
• Reading a peptide study

Sources

1. Baar, M. P., et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1), 132-147.e16. PMID: 28340339
2. Grey Peptides encyclopedia entry for FOXO4-DRI: class (D-retro-inverso design), status (no FDA application; no trial published or recruiting; Drugs@FDA read September 30, 2026), WADA 2026 and 2027 S0 inferred. Read October 3, 2026.
3. Bourgeois, B., et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun, 16(1), 5672. PMID: 40593617
4. Zhang, C., et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), 12(2), 1272-1284. PMID: 31959736
5. Huang, Y., et al. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol, 9, 677576. PMID: 33996787
6. Han, X., et al. (2022). FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med, 26(11), 3269-3280. PMID: 35510614
7. Li, Y., et al. (2024). FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol, 195, 112522. PMID: 39025385
8. Kong, Y. X., et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol, 8(1), 299. PMID: 39994346
9. Liu, Y., et al. (2023). FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol, 396(10), 2393-2403. PMID: 37074394
10. Born, E., et al. (2023). Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation, 147(8), 650-666. PMID: 36515093
11. Nambiar, A., et al. (2023). Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine, 90, 104481. PMID: 36857968
12. Farr, J. N., et al. (2024). Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med, 30(9), 2605-2612. PMID: 38956196
13. Gonzales, M. M., et al. (2022). Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial. J Prev Alzheimers Dis, 9(1), 22-29. PMID: 35098970
14. Chin, A. F., et al. (2023). Senolytic treatment reduces oxidative protein stress in an aging male murine model of post-traumatic osteoarthritis. Aging Cell, 22(11), e13979. PMID: 37749958
15. Silva, M., et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials, 25(1), 698. PMID: 39434114
16. Farr, J. N., et al. (2025). Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging Cell, 24(5), e14489. PMID: 39823170

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.